-
Je něco špatně v tomto záznamu ?
The decrease of mean platelet volume after extracorporeal LDL-cholesterol elimination
M. Blaha, M. Kostal, M. Lanska, V. Blaha, I. Foralova, S. Filip, M. Kubisova, J. Maly,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- biologické markery krev MeSH
- časové faktory MeSH
- dospělí MeSH
- hyperlipoproteinemie typ II krev diagnóza terapie MeSH
- LDL-cholesterol krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- prediktivní hodnota testů MeSH
- separace krevních složek * MeSH
- trombocyty patologie MeSH
- velikost buňky * MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVE: Mean platelet volume is arousing increasing interest as a new independent cardiovascular risk factor. Large platelets are likely to be more reactive. If mean platelet volume would drop after LDL-lowering therapy, decreased MPV could be one of the markers of successful therapy. Therefore, we investigated mean platelet volume after extracorporeal LDL-cholesterol elimination. METHODS: Mean platelet volume was investigated in patients with severe familial hypercholesterolemia long-term treated (3-12 years) by LDL-apheresis (immunoapheresis) or cascade filtration. Plasma was obtained by centrifugation. Adsorbers Lipopak 400 were used for immunoapheresis and filters Evaflux 4A were used for cascade filtration. 95 pair samples were measured (before and after the procedures) in a group of 12 patients--each patient 8 times in 4 years. RESULTS: Mean platelet volume before the procedures was 10.891 fl, CI 10.25-11.53. Mean platelet volume after the procedures decreased--10.478 fl, CI 09.84-11.11. The difference is statistically significant (p = 0.036). Mean platelet volume did not correlate with age, sex, platelet count, duration of therapy. At the same time, we used rheohemapheresis in the therapy of 40 patients with age-related macular degeneration. But mean platelet volume was not changed. CONCLUSION: Mean platelet volume is easily available and is often disregarded, and sometimes may suggest the need for a careful assessment in patients with familial hypercholesterolemia. Mean platelet volume could be one of the markers of therapeutic efficacy in patients with familial hypercholesterolemia treated by extracorporeal LDL-cholesterol elimination that is simple and inexpensive.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031672
- 003
- CZ-PrNML
- 005
- 20131003095840.0
- 007
- ta
- 008
- 131002s2013 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.atherosclerosissup.2012.10.019 $2 doi
- 035 __
- $a (PubMed)23357146
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Blaha, M $u 2nd Department of Internal Medicine, Charles University School of Medicine and Teaching Hospital, Hradec Králové, Czech Republic. blaham@email.cz
- 245 14
- $a The decrease of mean platelet volume after extracorporeal LDL-cholesterol elimination / $c M. Blaha, M. Kostal, M. Lanska, V. Blaha, I. Foralova, S. Filip, M. Kubisova, J. Maly,
- 520 9_
- $a OBJECTIVE: Mean platelet volume is arousing increasing interest as a new independent cardiovascular risk factor. Large platelets are likely to be more reactive. If mean platelet volume would drop after LDL-lowering therapy, decreased MPV could be one of the markers of successful therapy. Therefore, we investigated mean platelet volume after extracorporeal LDL-cholesterol elimination. METHODS: Mean platelet volume was investigated in patients with severe familial hypercholesterolemia long-term treated (3-12 years) by LDL-apheresis (immunoapheresis) or cascade filtration. Plasma was obtained by centrifugation. Adsorbers Lipopak 400 were used for immunoapheresis and filters Evaflux 4A were used for cascade filtration. 95 pair samples were measured (before and after the procedures) in a group of 12 patients--each patient 8 times in 4 years. RESULTS: Mean platelet volume before the procedures was 10.891 fl, CI 10.25-11.53. Mean platelet volume after the procedures decreased--10.478 fl, CI 09.84-11.11. The difference is statistically significant (p = 0.036). Mean platelet volume did not correlate with age, sex, platelet count, duration of therapy. At the same time, we used rheohemapheresis in the therapy of 40 patients with age-related macular degeneration. But mean platelet volume was not changed. CONCLUSION: Mean platelet volume is easily available and is often disregarded, and sometimes may suggest the need for a careful assessment in patients with familial hypercholesterolemia. Mean platelet volume could be one of the markers of therapeutic efficacy in patients with familial hypercholesterolemia treated by extracorporeal LDL-cholesterol elimination that is simple and inexpensive.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 12
- $a separace krevních složek $7 D001781
- 650 _2
- $a trombocyty $x patologie $7 D001792
- 650 12
- $a velikost buňky $7 D048429
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperlipoproteinemie typ II $x krev $x diagnóza $x terapie $7 D006938
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kostal, M $u -
- 700 1_
- $a Lanska, M $u -
- 700 1_
- $a Blaha, V $u -
- 700 1_
- $a Foralova, I $u -
- 700 1_
- $a Filip, S $u -
- 700 1_
- $a Kubisova, M $u -
- 700 1_
- $a Maly, J $u -
- 773 0_
- $w MED00006853 $t Atherosclerosis. Supplements $x 1878-5050 $g Roč. 14, č. 1 (2013), s. 77-81
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23357146 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20131003100358 $b ABA008
- 999 __
- $a ok $b bmc $g 995759 $s 830117
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 14 $c 1 $d 77-81 $i 1878-5050 $m Atherosclerosis supplements $n Atheroscler Suppl $x MED00006853
- LZP __
- $a Pubmed-20131002